Cargando…

mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation and New Bone Formation in vitro and in vivo

Introduction: Spondyloarthritis (SpA) is characterized by inflammation, articular bone erosions and pathologic new bone formation. Targeting TNFα or IL-17A with current available therapies reduces inflammation in SpA, however, treatment of the bone pathology in SpA remains an unmet clinical need. Ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Sijia, van Tok, Melissa N., Knaup, Véronique L., Kraal, Lianne, Pots, Désiree, Bartels, Lina, Gravallese, Ellen M., Taurog, Joel D., van de Sande, Marleen, van Duivenvoorde, Leonie M., Baeten, Dominique L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065603/ https://www.ncbi.nlm.nih.gov/pubmed/32194539 http://dx.doi.org/10.3389/fimmu.2019.02344

Ejemplares similares

Innate Immune Activation Can Trigger Experimental Spondyloarthritis in HLA-B27/Huβ2m Transgenic Rats
por: van Tok, Melissa N., et al.
Publicado: (2017)

The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling
por: van Tok, Melissa N., et al.
Publicado: (2018)

Non-conventional forms of HLA-B27 are expressed in spondyloarthritis joints and gut tissue
por: Rysnik, Oliwia, et al.
Publicado: (2016)

Dual Blockade of TNF and IL-17A Inhibits Inflammation and Structural Damage in a Rat Model of Spondyloarthritis
por: Hammoura, Ihsan, et al.
Publicado: (2022)

Paradoxical Augmentation of Experimental Spondyloarthritis by RORC Inhibition in HLA-B27 Transgenic Rats
por: van Tok, Melissa N., et al.
Publicado: (2021)

Transmembrane TNF drives osteoproliferative joint inflammation reminiscent of human spondyloarthritis
por: Kaaij, Merlijn H., et al.
Publicado: (2020)

Data showing non-conventional HLA-B27 expression in axial joints and gut tissue from B27 transgenic rats, and in frozen and paraffin-fixed synovial SpA tissue
por: Rysnik, Oliwia, et al.
Publicado: (2016)

Relative overexpression of membrane-bound versus soluble TNF in spondyloarthritis
por: Ambarus, Carmen A, et al.
Publicado: (2012)

Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort
por: de Winter, Janneke J., et al.
Publicado: (2018)

The Role of the IL-23/IL-17 Axis in Disease Initiation in Spondyloarthritis: Lessons Learned From Animal Models
por: Mandour, Mohamed, et al.
Publicado: (2021)

Blockade of the mTOR signaling pathway with rapamycin ameliorates aristolochic acid nephropathy
por: Wu, Minmin, et al.
Publicado: (2020)

Insulin-Like Growth Factor I Does Not Drive New Bone Formation in Experimental Arthritis
por: van Tok, Melissa N., et al.
Publicado: (2016)

Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis
por: de Winter, Janneke J, et al.
Publicado: (2019)

Progression From Subclinical Inflammation to Overt Spondyloarthritis in First‐Degree Relatives of Patients in Association With HLA–B27: The Pre‐Spondyloarthritis Cohort
por: de Jong, Henriëtte M. Y., et al.
Publicado: (2022)

Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain
por: de Winter, Janneke, et al.
Publicado: (2018)

Anti-IL-17A treatment reduces serum inflammatory, angiogenic and tissue remodeling biomarkers accompanied by less synovial high endothelial venules in peripheral spondyloarthritis
por: Kaaij, Merlijn H., et al.
Publicado: (2020)

Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
por: Braun, Juergen, et al.
Publicado: (2023)

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
por: Murray, James T., et al.
Publicado: (2018)

Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor
por: Artoni, Filippo, et al.
Publicado: (2023)

Patients’ and rheumatologists’ perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis
por: van Boheemen, Laurette, et al.
Publicado: (2020)

Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort
por: Abawi, Ozair, et al.
Publicado: (2017)

Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines
por: Lin, Hugo You-Hsien, et al.
Publicado: (2014)

The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling
por: Yoon, Mee-Sup
Publicado: (2017)

The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
por: Lawrence, Jessica, et al.
Publicado: (2018)

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
por: Querfurth, Henry, et al.
Publicado: (2021)

Measuring quality of life of patients with axial spondyloarthritis for economic evaluation
por: Hernandez Alava, Monica, et al.
Publicado: (2022)

Age at onset in axial spondyloarthritis around the world: data from the Assessment in SpondyloArthritis international Society Peripheral Involvement in Spondyloarthritis study
por: Boel, Anne, et al.
Publicado: (2021)

Expansion of Interleukin‐22– and Granulocyte–Macrophage Colony‐Stimulating Factor–Expressing, but Not Interleukin‐17A–Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With Spondyloarthritis
por: Blijdorp, Iris C. J., et al.
Publicado: (2019)

Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis
por: de Winter, Janneke J., et al.
Publicado: (2016)

GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer
por: Scott, Kenneth L., et al.
Publicado: (2009)

Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
por: Seto, Belinda
Publicado: (2012)

mTOR kinase structure, mechanism and regulation by the rapamycin-binding domain
por: Yang, Haijuan, et al.
Publicado: (2013)

Brain size is controlled by the mammalian target of rapamycin (mTOR) in mice
por: Kim, Woo-Yang
Publicado: (2015)

The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment
por: Maiese, Kenneth
Publicado: (2020)

Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy
por: Zhao, Wei, et al.
Publicado: (2023)

IL-17 in spondyloarthritis: is the T-party over?
por: Yeremenko, Nataliya, et al.
Publicado: (2011)

Hyaluronic Acid in Synovial Fluid Prevents Neutrophil Activation in Spondyloarthritis
por: Mol, Sanne, et al.
Publicado: (2023)

Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort
por: Turina, Maureen C, et al.
Publicado: (2017)

Regulation of Gene Expression in Hepatic Cells by the Mammalian Target of Rapamycin (mTOR)
por: Jimenez, Rosa H., et al.
Publicado: (2010)

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
por: García-Martínez, Juan M., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_h0lmh1aenn3a3hv4858d58vr8i